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Long- term effectiveness of live herpes zoster 
vaccine in patients with rheumatoid arthritis 
subsequently treated with tofacitinib
Herpes zoster (HZ) incidence is higher in patients with rheuma-
toid arthritis (RA) compared with the general population,1 and it 
may be further increased with disease- modifying antirheumatic 
drugs (DMARDs).2 Tofacitinib is an oral Janus kinase inhibitor 
for the treatment of RA. Real- world data indicate that HZ inci-
dence is approximately twofold higher with tofacitinib versus 
biologic DMARDs (bDMARDs).3
Current American College of Rheumatology guidelines condi-
tionally recommend that patients with RA aged ≥50 years 
receive HZ vaccine prior to tofacitinib or bDMARDs.4 We previ-
ously evaluated the immunogenicity of a live attenuated zoster 
vaccine (LZV), administered 2–3 weeks prior to tofacitinib or 
placebo with background conventional synthetic DMARDs. 
Both groups had similar varicella zoster virus (VZV)- specific 
immune responses, and overall immune responses were compa-
rable with those of healthy volunteers in previous studies.5 We 
have now followed this patient cohort in an open- label, long- 
term extension (LTE) study of tofacitinib.
Patients enrolled in the index study (A3921237; 
NCT02147587)5 could join ORAL Sequel (LTE study; 
A3921024; NCT00413699) 14 weeks post- vaccination, where 
they received open- label tofacitinib 5 or 10 mg two times per 
day (online supplementary figure S1); background RA therapy 
was also allowed. Patients were followed for 27 months. Post- 
vaccination, adverse events (AEs), including discontinuations 
due to AEs, were recorded during the study within 28 days of the 
last dose. Incidence rates (IRs; patients with events/100 patient- 
years (PY)) and 95% CIs for HZ post- vaccination were calcu-
lated based on time to first event (patients not reporting an event 
were censored at last treatment dose). Short- term VZV- specific 
immunity was evaluated at baseline and week 6 post- vaccination 
during the index study.
Vaccine- related AEs in the index study included mild injection- 
site pain, swelling, redness, itching and myalgia. Disseminated 
vaccine- strain varicella was also reported in a patient with no 
previous exposure to VZV.5 After rollover into ORAL Sequel, 100 
patients received an average tofacitinib dose of 5 mg (n=46) or 
10 mg (n=54) two times per day. Mean (range) tofacitinib expo-
sure was 489 (46–811) days and overall exposure was 139 PY.
LZV did not provide adequate protection to all patients. 
Five HZ cases (#1–5) occurred in the LTE study 218, 280, 
748, 741 and 544 days post- vaccination, respectively (IR=3.60 
(1.17, 8.39); table 1). Cases #1–4 were monodermatomal and 
case #5 involved five dermatomes. All HZ events were mild/
moderate in severity and resolved with antiviral treatment.
VZV humoral immunity (immunoglobulin G (IgG) titre) 
and VZV cell- mediated immunity (interferon-γ enzyme- 
linked immunosorbent spot (ELISPOT)) in patients receiving 
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Table 1 Patient profiles of HZ cases
Case #1 Case #2 Case #3 Case #4 Case #5
Age, years 65 60 77 74 74
Sex Female Male Female Male Male
Race White White White White White
Study drug
(A3921237)
Tofacitinib
5 mg two times per day
Tofacitinib
5 mg two times per day
Placebo Placebo Placebo
Study drug
(ORAL Sequel)
Tofacitinib
10 mg two times per day
Tofacitinib
5 mg two times per day
Tofacitinib
5 mg two times per day
Tofacitinib
10 mg two times per day
Tofacitinib
10 mg two times per day
Background RA drugs MTX 15 mg/week
Prednisone 5 mg/day
MTX 20 mg/week None None MTX 20 mg/week
Type of HZ Monodermatomal Monodermatomal Monodermatomal Monodermatomal 5 dermatomes
Severity of HZ* Moderate Mild Moderate Mild Mild
Duration of HZ, days 49 14 14 16 10
Action to study drug No action taken Stopped temporarily No action taken No action taken Stopped temporarily
Outcome of HZ Resolved with acyclovir Resolved with famciclovir Resolved with acyclovir 
and azithromycin
Resolved with 
valacyclovir
Resolved with 
valacyclovir
Occurrence of HZ           
  Time after LZV vaccination, days 218 280 748 741 544
  Time after initiation of tofacitinib, days 202 267 702 699 466
VZV humoral immunity (IgG titre), U/mL†           
  Baseline 224.3 36.9 96.6 237.3 208.3
  Week 6 444.0 70.9 186.9 231.5 222.5
  Change from baseline (fold rise at week 6) 1.98 1.92 1.93 0.98 1.07
VZV cell- mediated immunity, SFCs/106 PBMCs‡           
  Baseline 25 41 25 25 25
  Week 6 25 76 51 25 25
  Change from baseline (fold rise at week 6) 1.00 1.85 2.04 1.00 1.00
*Determined by the investigator.
†Assessed by gpELISA (PPD Vaccines and Biologics); mean VZV IgG titres in patients receiving tofacitinib and placebo, respectively, in the index study were 201 and 182 U/mL at baseline and  
403 and 323 U/mL at week 6 (fold rise at week 6 was 2.11 with tofacitinib and 1.74 with placebo).5
‡Assessed by IFNγ ELISPOT (Pfizer Inc Vaccine Research Unit, Pearl River, New York, USA); limit of detection was 25 SFCs/106 PBMCs; values in the table shown as 25 SFCs/106 PBMCs may be 
below this threshold; mean VZV cell- mediated immunity in patients receiving tofacitinib and placebo, respectively, in the index study was 48 SFCs/106 PBMCs and 43 SFCs/106 PBMCs at baseline, 
and 70 SFCs/106 PBMCs and 56 SFCs/106 PBMCs at week 6 (fold rise at week 6 was 1.50 with tofacitinib and 1.29 with placebo).5
ELISPOT, enzyme- linked immunosorbent spot; gpELISA, glycoprotein- based enzyme- linked immunosorbent assay; HZ, herpes zoster; IFNγ, interferon gamma; IgG, immunoglobulin G; LZV, live zoster 
vaccine; MTX, methotrexate; PBMCs, peripheral blood mononuclear cells; RA, rheumatoid arthritis; SFCs, spot- forming cells; VZV, varicella zoster virus.
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tofacitinib or placebo in the index study5 are shown in table 1. 
In terms of immunity after LZV in this analysis, cases #1, 
#4 and #5 had undetectable VZV cell- mediated immunity, 
at baseline and week 6; cases #2 (patient received tofaci-
tinib 5 mg two times per day in index and LTE studies) and 
#3 (patient received placebo and tofacitinib 5 mg two times 
per day in index and LTE studies, respectively) responded 
adequately to vaccination by both IgG and ELISPOT measures 
but had lower than average VZV IgG levels at baseline (case 
#2: 36.9 U/mL vs average of 201 U/mL; case #3: 96.6 U/mL 
vs average of 182 U/mL) and week 6 (case #2: 70.9 U/mL 
vs average of 403 U/mL; case #3: 186.9 U/mL vs average of 
323 U/mL; table 1).
HZ incidence was similar to that in patients receiving 
tofacitinib in phase 1/2/3/LTE studies up to 9.5 years (IR=3.6 
(3.4, 3.9); n=782/7061]),6 although the present analysis was 
limited due to the small number of patients, and 95% CIs were 
wide. Cell- mediated responses in cases #2 and #3 may have 
been short- lived; however, serial longitudinal data are required 
to confirm this.
These results suggest that LZV may not provide adequate 
long- term protection, as previously demonstrated in healthy 
individuals aged ≥60 years 3 years post- vaccination, in which 
HZ risk was reduced by 51%.2 While it is possible that LZV 
booster vaccinations may improve vaccine efficacy, to date there 
is a lack of data on the use and timing of booster vaccinations, 
and no recommendations on the use of LZV booster vaccina-
tions currently exist. This highlights the importance of evalu-
ating the newly approved subunit non- live vaccine (Shingrix) in 
patients with RA receiving tofacitinib.
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